Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | F13A1 | P00488 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | TGM1 | P22735 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PREP | P48147 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205102 | 0.98 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL8396585 | 0.98 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| Bicarbonate SCHEMBL7266316 | 0.97 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL8395084 | 0.97 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL8393648 | 0.94 | LMNA (0.58) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL9185615 | 0.89 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL29652185 | 0.88 | LMNA (0.52) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL14451403 | 0.88 | LMNA (0.52) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL26246109 | 0.88 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL3947244 | 0.87 | LMNA (0.51) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022084446-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2022-04-28 | — | — | WO | disclosed |
| EP-3118203-A1 | CDK INHIBITORS | G1 Therapeutics, Inc. (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2632467-B1 | CDK INHIBITORS | G1 THERAPEUTICS INC (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2955183-A1 | CDK INHIBITORS | G1 Therapeutics, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9102682-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150031880-A1 | CDK Inhibitors | PHARMACOSMOS A/S (DK) | 2015-01-29 | — | — | US | disclosed |
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014144326-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144740-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144847-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-6127372-A | FOR TREATMENT OR PREVENTION OF VIRAL DISEASES, ESPECIALLY AIDS OR HIV | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0749421-B1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMA (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| EP-0749421-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| WO-1995024385-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | CDK6, CCNC, MCL1 | ALDH1A1 1726/4885MEN1 3666/4885KMT2A 513/4885 |
| US-20150031880-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | ALDH1A1 2981/4885MEN1 2275/4885KMT2A 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.